title: ÐÑÐµÐ½ÐºÐ° ÑÐºÑÐ¿ÑÐµÑÑÐ¸Ð¸ Ð³ÐµÐ½Ð¾Ð², Ð¸Ð½Ð´ÑÑÐ¸ÑÑÐµÐ¼ÑÑ Ð¸Ð½ÑÐµÑÑÐµÑÐ¾Ð½Ð°Ð¼Ð¸ 1 ÑÐ¸Ð¿Ð° Ñ Ð¿Ð°ÑÐ¸ÐµÐ½ÑÐ¾Ð² Ñ Ð°ÑÑÐ¾Ð¸Ð¼Ð¼ÑÐ½Ð½ÑÐ¼Ð¸ Ð·Ð°Ð±Ð¾Ð»ÐµÐ²Ð°Ð½Ð¸ÑÐ¼Ð¸
title: Ð²ÑÐ¿ÑÑÐºÐ½Ð°Ñ ÐºÐ²Ð°Ð»Ð¸ÑÐ¸ÐºÐ°ÑÐ¸Ð¾Ð½Ð½Ð°Ñ ÑÐ°Ð±Ð¾ÑÐ° Ð±Ð°ÐºÐ°Ð»Ð°Ð²ÑÐ°
titleType: Subtitle
title: Assessment of gene expression induced by type 1 interferons in patients with autoimmune diseases
Creators: name: ÐÑÐ»ÐºÐ¸Ð´Ð¶Ð°Ð½, Ð Ð¸Ð¼Ð¼Ð°
Publisher: name: Ð¡Ð°Ð½ÐºÑ-ÐÐµÑÐµÑÐ±ÑÑÐ³ÑÐºÐ¸Ð¹ Ð¿Ð¾Ð»Ð¸ÑÐµÑÐ½Ð¸ÑÐµÑÐºÐ¸Ð¹ ÑÐ½Ð¸Ð²ÐµÑÑÐ¸ÑÐµÑ ÐÐµÑÑÐ° ÐÐµÐ»Ð¸ÐºÐ¾Ð³Ð¾
Year: 2021
Subjects: ÐÐ¤Ð-i-Ð¸Ð½Ð´ÐµÐºÑ
taqman Ð·Ð¾Ð½Ð´Ñ
Ð°ÑÑÐ¾Ð¸Ð¼Ð¼ÑÐ½Ð½ÑÐµ Ð·Ð°Ð±Ð¾Ð»ÐµÐ²Ð°Ð½Ð¸Ñ
IFN-i-index
taqman probes
autoimmune diseases

description: Ð¢ÐµÐ¼Ð° Ð²ÑÐ¿ÑÑÐºÐ½Ð¾Ð¹ ÐºÐ²Ð°Ð»Ð¸ÑÐ¸ÐºÐ°ÑÐ¸Ð¾Ð½Ð½Ð¾Ð¹ ÑÐ°Ð±Ð¾ÑÑ: Â«ÐÑÐµÐ½ÐºÐ° ÑÐºÑÐ¿ÑÐµÑÑÐ¸Ð¸ Ð³ÐµÐ½Ð¾Ð², Ð¸Ð½Ð´ÑÑÐ¸ÑÑÐµÐ¼ÑÑ Ð¸Ð½ÑÐµÑÑÐµÑÐ¾Ð½Ð°Ð¼Ð¸ 1 ÑÐ¸Ð¿Ð° Ñ Ð¿Ð°ÑÐ¸ÐµÐ½ÑÐ¾Ð² Ñ Ð°ÑÑÐ¾Ð¸Ð¼Ð¼ÑÐ½Ð½ÑÐ¼Ð¸ Ð·Ð°Ð±Ð¾Ð»ÐµÐ²Ð°Ð½Ð¸ÑÐ¼Ð¸Â». Ð ÑÐ¾Ð´Ðµ Ð²ÑÐ¿Ð¾Ð»Ð½ÐµÐ½Ð¸Ñ ÑÐ°Ð±Ð¾ÑÑ Ð±ÑÐ» ÑÐ°Ð·ÑÐ°Ð±Ð¾ÑÐ°Ð½ ÑÐµÑÑ Ð´Ð»Ñ Ð¾Ð¿ÑÐµÐ´ÐµÐ»ÐµÐ½Ð¸Ñ ÑÑÐ¾Ð²Ð½Ñ ÑÐºÑÐ¿ÑÐµÑÑÐ¸Ð¸ Ð¸Ð½ÑÐµÑÑÐµÑÐ¾Ð½Ð¾Ð² 1 ÑÐ¸Ð¿Ð° Ñ Ð¿Ð°ÑÐ¸ÐµÐ½ÑÐ¾Ð² Ñ Ð°ÑÑÐ¾Ð¸Ð¼Ð¼ÑÐ½Ð½ÑÐ¼Ð¸ Ð·Ð°Ð±Ð¾Ð»ÐµÐ²Ð°Ð½Ð¸ÑÐ¼Ð¸, Ð¾ÑÐ½Ð¾Ð²Ð°Ð½Ð½ÑÐ¹ Ð½Ð° Ð¼ÐµÑÐ¾Ð´Ðµ Ð¿Ð¾Ð»Ð¸Ð¼ÐµÑÐ°Ð·Ð½Ð¾Ð¹ ÑÐµÐ¿Ð½Ð¾Ð¹ ÑÐµÐ°ÐºÑÐ¸Ð¸ Ð² ÑÐµÐ¶Ð¸Ð¼Ðµ ÑÐµÐ°Ð»ÑÐ½Ð¾Ð³Ð¾ Ð²ÑÐµÐ¼ÐµÐ½Ð¸ Ñ Ð¸ÑÐ¿Ð¾Ð»ÑÐ·Ð¾Ð²Ð°Ð½Ð¸ÐµÐ¼ TaqMan Ð·Ð¾Ð½Ð´Ð¾Ð². Ð¢ÐµÑÑ Ð±Ð°Ð·Ð¸ÑÑÐµÑÑÑ Ð½Ð° Ð¾ÑÐµÐ½ÐºÐµ ÑÑÐµÐ´Ð½ÐµÐ¹ ÑÐºÑÐ¿ÑÐµÑÑÐ¸Ð¸ 5 Ð³ÐµÐ½Ð¾Ð² (IFI44L, IFI44, IFIT3, LY6E, MX1), Ð¸Ð½Ð´ÑÑÐ¸ÑÑÐµÐ¼ÑÑ Ð¸Ð½ÑÐµÑÑÐµÑÐ¾Ð½Ð°Ð¼Ð¸ ÑÐ¸Ð¿Ð° 1. ÐÑÑÐµÐ¼ Ð¸Ð·ÑÑÐµÐ½Ð¸Ñ Ð²ÑÐ±Ð¾ÑÐºÐ¸ Ð·Ð´Ð¾ÑÐ¾Ð²ÑÑ Ð¸Ð½Ð´Ð¸Ð²Ð¸Ð´ÑÑÐ¼Ð¾Ð² Ð±ÑÐ» ÑÑÑÐ°Ð½Ð¾Ð²Ð»ÐµÐ½ Ð½Ð¾ÑÐ¼Ð°Ð»ÑÐ½ÑÐ¹ Ð´Ð¸Ð°Ð¿Ð°Ð·Ð¾Ð½ Ð²Ð°ÑÐ¸Ð°ÑÐ¸Ð¹ ÐÐ¤Ð1-Ð¸Ð½Ð´ÐµÐºÑÐ°. ÐÑÑÐ»ÐµÐ´Ð¾Ð²Ð°Ð½Ð¸Ðµ ÐÐ¤Ð1-Ð¸Ð½Ð´ÐµÐºÑÐ° Ð¿ÑÐ¾Ð´ÐµÐ¼Ð¾Ð½ÑÑÑÐ¸ÑÐ¾Ð²Ð°Ð»Ð¾, ÑÑÐ¾ ÑÑÐ¾Ñ Ð¿Ð¾ÐºÐ°Ð·Ð°ÑÐµÐ»Ñ Ð´ÐµÐ¹ÑÑÐ²Ð¸ÑÐµÐ»ÑÐ½Ð¾ Ð¿ÑÐ¸Ð³Ð¾Ð´ÐµÐ½ Ð´Ð»Ñ Ð´ÐµÑÐµÐºÑÐ¸Ð¸ Ð¸Ð·Ð±ÑÑÐ¾ÑÐ½Ð¾Ð¹ Ð°ÐºÑÐ¸Ð²Ð°ÑÐ¸Ð¸ Ð¸Ð½ÑÐµÑÑÐµÑÐ¾Ð½Ð¾Ð²Ð¾Ð³Ð¾ ÐºÐ°ÑÐºÐ°Ð´Ð°: Ð¼ÐµÐ´Ð¸Ð°Ð½Ñ Ð·Ð½Ð°ÑÐµÐ½Ð¸Ð¹ ÐÐ¤Ð1-Ð¸Ð½Ð´ÐµÐºÑÐ° Ñ Ð¿Ð°ÑÐ¸ÐµÐ½ÑÐ¾Ð² Ñ ÑÐ²ÐµÐ½Ð¸Ð»ÑÐ½ÑÐ¼ Ð´ÐµÑÐ¼Ð°ÑÐ¾Ð¼Ð¸Ð¾Ð·Ð¸ÑÐ¾Ð¼ (Ð®ÐÐ) Ð¸ ÑÐ¸ÑÑÐµÐ¼Ð½Ð¾Ð¹ ÐºÑÐ°ÑÐ½Ð¾Ð¹ Ð²Ð¾Ð»ÑÐ°Ð½ÐºÐ¾Ð¹ (Ð¡ÐÐ) ÑÑÑÐµÑÑÐ²ÐµÐ½Ð½Ð¾ Ð¿ÑÐµÐ²ÑÑÐ°Ð»Ð¸ ÑÐ°ÐºÐ¾Ð²ÑÐµ Ð² Ð³ÑÑÐ¿Ð¿Ðµ Ð·Ð´Ð¾ÑÐ¾Ð²ÑÑ Ð´Ð¾Ð½Ð¾ÑÐ¾Ð². Ð¡ÑÐµÐ´Ð½ÐµÐµ Ð·Ð½Ð°ÑÐµÐ½Ð¸Ðµ ÐÐ¤Ð1-Ð¸Ð½Ð´ÐµÐºÑÐ° Ñ Ð¿Ð°ÑÐ¸ÐµÐ½ÑÐ¾Ð² Ñ Ð®ÐÐ Ð² Ð°ÐºÑÐ¸Ð²Ð½Ð¾Ð¹ ÑÐ°Ð·Ðµ Ð·Ð°Ð±Ð¾Ð»ÐµÐ²Ð°Ð½Ð¸Ñ (Ð¾Ð±Ð¾ÑÑÑÐµÐ½Ð¸Ðµ) Ð±ÑÐ»Ð¾ ÑÑÑÐµÑÑÐ²ÐµÐ½Ð½Ð¾ Ð²ÑÑÐµ, ÑÐµÐ¼ Ñ Ð¿Ð°ÑÐ¸ÐµÐ½ÑÐ¾Ð² Ð² Ð½ÐµÐ°ÐºÑÐ¸Ð²Ð½Ð¾Ð¹ ÑÐ°Ð·Ðµ (ÑÐµÐ¼Ð¸ÑÑÐ¸Ñ). ÐÐºÐ¾Ð»Ð¾ Ð¿Ð¾Ð»Ð¾Ð²Ð¸Ð½Ñ Ð¿Ð°ÑÐ¸ÐµÐ½ÑÐ¾Ð² Ñ ÐºÐ»Ð¸Ð½Ð¸ÐºÐ¾-Ð»Ð°Ð±Ð¾ÑÐ°ÑÐ¾ÑÐ½ÑÐ¼Ð¸ Ð¿ÑÐ¸Ð·Ð½Ð°ÐºÐ°Ð¼Ð¸ Ð¸Ð½ÑÐµÑÑÐµÑÐ¾Ð½Ð¾Ð¿Ð°ÑÐ¸Ð¸ (Ð½ÐµÐ´Ð¸ÑÑÐµÑÐµÐ½ÑÐ¸ÑÐ¾Ð²Ð°Ð½Ð½ÑÐµ Ð¸Ð½ÑÐµÑÑÐµÑÐ¾Ð½Ð¾Ð¿Ð°ÑÐ¸Ð¸) Ð¸Ð¼ÐµÑÑ Ð¿Ð¾Ð²ÑÑÐµÐ½Ð½ÑÐ¹ ÐÐ¤Ð1-Ð¸Ð½Ð´ÐµÐºÑ. ÐÐ·ÑÑÑ Ð½ÐµÑÐºÐ¾Ð»ÑÐºÐ¾ Ð¿Ð°ÑÐ¸ÐµÐ½ÑÐ¾Ð² Ð² Ð´Ð¸Ð½Ð°Ð¼Ð¸ÐºÐµ: ÑÐ½Ð¸Ð¶ÐµÐ½Ð¸Ðµ ÐÐ¤Ð1-Ð¸Ð½Ð´ÐµÐºÑÐ° Ð¿Ð¾ÑÐ»Ðµ ÐºÑÑÑÐ° ÑÐµÑÐ°Ð¿Ð¸Ð¸ Ð´Ð¾ÑÑÐ¾Ð²ÐµÑÐ½Ð¾. ÐÐ½Ð°ÑÐµÐ½Ð¸Ñ ÐÐ¤Ð1-Ð¸Ð½Ð´ÐµÐºÑÐ°, Ð¿Ð¾Ð»ÑÑÐµÐ½Ð½ÑÐµ Ñ Ð¿Ð¾Ð¼Ð¾ÑÑÑ Ð´Ð°Ð½Ð½Ð¾Ð³Ð¾ ÑÐµÑÑÐ°, Ð·Ð½Ð°ÑÐ¸Ð¼Ð¾ ÐºÐ¾ÑÑÐµÐ»Ð¸ÑÑÑÑ Ñ ÑÐ°Ð·Ð¾Ð¹ Ð·Ð°Ð±Ð¾Ð»ÐµÐ²Ð°Ð½Ð¸Ñ, Ð¸Ð½ÑÐµÐ½ÑÐ¸Ð²Ð½Ð¾ÑÑÑÑ ÑÐµÑÐ°Ð¿Ð¸Ð¸ Ð¸ Ð¿Ð¾Ð·Ð²Ð¾Ð»ÑÑÑ Ð¾ÑÐµÐ½Ð¸ÑÑ Ð¾Ð±ÑÐµÐµ ÑÐ¾ÑÑÐ¾ÑÐ½Ð¸Ðµ Ð¿Ð°ÑÐ¸ÐµÐ½ÑÐ° Ð¸ ÑÐ¾Ð»Ñ ÐÐ¤Ð Ð² Ð¿Ð°ÑÐ¾Ð³ÐµÐ½ÐµÐ·Ðµ Ð·Ð°Ð±Ð¾Ð»ÐµÐ²Ð°Ð½Ð¸Ñ.
description: The topic of the final qualifying work: "Evaluation of the expression of genes induced by type 1 interferons in patients with autoimmune diseases." In the course of the work, a test was developed to determine the expression level of type 1 interferons in patients with autoimmune diseases. The method is the real-time polymerase chain reaction method using TaqMan probes. The test is based on the assessment of the average expression of 5 genes (IFI44L, IFI44, IFIT3, LY6E, MX1) induced by type 1 interferons. By studying a sample of healthy individuals, a normal range of IFN1 index variations was established. The study of the IFN-1 index demonstrated that this indicator is suitable for detecting excessive activation of the interferon cascade: the median values of the IFN1-index in patients with JDM and SLE significantly exceeded those in the group of healthy donors. The average IFN-1 score in patients with JDM in the active phase of the disease (exacerbation) was significantly higher than in patients in the inactive phase (remission). About half of patients with clinical and laboratory signs of interferonopathy (undifferentiated interferonopathies) have an increased IFN1 score. At the same time, a significant increase in the IFN1 score is not typical for patients with systemic JIA, nonspecific aortoarteritis, eosinophilic fasciitis, and undifferentiated cutaneous vasculitis. Several patients were taken in dynamics: the decrease in the index after the course of therapy is significant. The IFN index values obtained using this test significantly correlate with the phase of the disease, the intensity of therapy and allow assessing the general condition of the patient and the role of IFN in the pathogenesis of the disease.